A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

Sasanlimab is an antibody to the programmed cell death protein 1 receptor. We report updated data of subcutaneous sasanlimab in non-small-cell lung cancer (NSCLC) and urothelial carcinoma dose expansion cohorts from a first-in-human phase Ib/II study. Patients were ≥18 years of age with NSCLC or uro...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ESMO open 2023-08, Vol.8 (4), p.101589-101589, Article 101589
Hauptverfasser:	Cho, B.C., Penkov, K., Bondarenko, I., Kurochkin, A., Pikiel, J., Ahn, H.K., Korożan, M.E., Osipov, M., Odintsova, S., Braiteh, F., Ribas, A., Grilley-Olson, J.E., Lugowska, I., Bonato, V., Damore, M.A., Yang, W., Jacobs, I.A., Bowers, M., Li, M., Johnson, M.L.
Format:	Artikel
Sprache:	eng
Schlagworte:	non-small-cell lung cancer Original Research PD-1 phase I sasanlimab urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!